We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+22.06%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
+$87.3M
Cap. Flow
-$105M
Cap. Flow %
-9.42%
Top 10 Hldgs %
48.85%
Holding
77
New
7
Increased
18
Reduced
19
Closed
8

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$29.7M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$15.7M
3
TVTX icon
Travere Therapeutics
TVTX
+$15.4M
4
ACOR
Acorda Therapeutics
ACOR
+$15M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.1M

Top Sells

Rank Stock Value
1
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$41.1M
2
NVRO
NEVRO CORP.
NVRO
+$30.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.6M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$21.8M
5
ANGO icon
AngioDynamics
ANGO
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 84.53%
2 Financials 0.24%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$99.8M 8.94%
5,503,182
-1,360,666
-20% -$26.6M
TVTX icon
2
Travere Therapeutics
TVTX
$5.16B
$77.6M 6.96%
3,469,271
+806,680
+30% +$15.4M
NVDQ
3
DELISTED
Novadaq Technologies Inc.
NVDQ
$59.9M 5.37%
5,174,209
-291,007
-5% -$3.16M
PGNX
4
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$56.7M 5.08%
8,951,169
– –
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$54.5M 4.88%
4,394,464
– –
ANGO icon
6
AngioDynamics
ANGO
$567M
$50.7M 4.54%
2,890,679
-716,603
-20% -$11.6M
HRTX icon
7
Heron Therapeutics
HRTX
$90.9M
$49.1M 4.4%
2,850,000
+1,599,896
+128% +$29.7M
LJPC
8
DELISTED
La Jolla Pharmaceutical Company
LJPC
$34.4M 3.09%
1,447,053
+165,680
+13% +$3.12M
XBI icon
9
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$33.1M 2.97%
+500,000
New +$30.9M
ENDP
10
DELISTED
Endo International plc
ENDP
$29.3M 2.63%
1,454,538
+425,736
+41% +$8.46M
PETX
11
DELISTED
Aratana Therapeutics, Inc.
PETX
$28.9M 2.59%
3,085,979
-342,886
-10% -$2.85M
ATRS
12
DELISTED
Antares Pharma, Inc.
ATRS
$25M 2.24%
14,885,393
– –
IOVA icon
13
Iovance Biotherapeutics
IOVA
$2.24B
$21.7M 1.95%
2,638,259
-532,500
-17% -$4.5M
SCTL
14
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$21.7M 1.94%
2,731,846
+434,850
+19% +$3.49M
ARLZ
15
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$21.4M 1.92%
4,406,990
+300,000
+7% +$1.37M
HZNP
16
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$19M 1.71%
1,050,000
+550,000
+110% +$10.7M
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$18.9M 1.7%
410,000
+232,600
+131% +$13.1M
GNMX
18
DELISTED
Aevi Genomic Medicine Inc
GNMX
$18.8M 1.68%
3,370,306
– –
TLGT
19
DELISTED
Teligent, Inc
TLGT
$16.7M 1.5%
220,190
-31,460
-13% -$2.5M
ADXS
20
DELISTED
Advaxis Inc
ADXS
$16.7M 1.5%
104,312
-8,389
-7% -$1.37M
RXDX
21
DELISTED
Ignyta, Inc.
RXDX
$14.2M 1.27%
2,256,546
– –
DVAX
22
DELISTED
Dynavax Technologies
DVAX
$14.1M 1.27%
1,347,810
+800,000
+146% +$11.5M
BDSI
23
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$14M 1.26%
5,188,794
– –
TEVA icon
24
Teva Pharmaceuticals
TEVA
$36.1B
$13.8M 1.24%
+300,000
New +$15.7M
AEGR
25
DELISTED
Aegerion Pharmaceuticals
AEGR
$13M 1.16%
4,361,291
+351,000
+9% +$608K
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Broadfin Capital held 77 positions worth $1.12B, up 8.5% from $1.03B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Broadfin Capital withdrew a net $105M in Q3 2016, closing 8 positions and reducing 19 holdings. Its most notable exit was Genomic Health, Inc., an estimated $7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 73% a quarter earlier, followed by Financials and Technology.

Against the trend, Broadfin Capital opened a new position in Teva Pharmaceuticals worth $13.8M.

  • Broadfin Capital's largest Q3 2016 buy was Teva Pharmaceuticals: 300,000 shares worth $13.8M.
  • Broadfin Capital added most to Heron Therapeutics in Q3 2016, an estimated $29.7M increase.
  • Broadfin Capital's biggest Q3 2016 reduction was RAPTOR PHARMACEUTICAL CORP COM STK (DE), cutting an estimated $41.1M.
  • Broadfin Capital fully exited Genomic Health, Inc. in Q3 2016, selling an estimated $7M.
  • Broadfin Capital's ten largest holdings make up 49% of its $1.12B portfolio in Q3 2016.
  • Broadfin Capital opened 7 new positions and closed 8 in Q3 2016.
  • Broadfin Capital's portfolio value rose 8.5% quarter-over-quarter to $1.12B.

Based on Broadfin Capital's 13F filing for Q3 2016, filed 14 Nov 2016.